Immunodeficient and immunosuppressed mice as models to test anti- Pneumocystis carinii drugs

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 251-258

  Walzer, Peter D ^a,b   Runck, Jennifer ^b   Steele, Paul ^b   White, Michael ^b   Linke, Michael J ^a,b   Sidman, Charles L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; ATOVAQUONE; CEFRADINE; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; DEXAMETHASONE; EPIROPRIM; METHYLPREDNISOLONE ACETATE; PENTAMIDINE; PRIMAQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SCID MOUSE; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0031050621     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.251     Document Type: Article

References (42)

1. Bartlett, M. S., T. D. Edlind, C. H. Alee, R. Dean, M. M. Shaw, M. M. Durkin, S. F. Queener, and J. W. Smith. 1994. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. Antimicrob. Agents Chemother. 38:1834-1837.
2. Bartlett, M. S., S. F. Queener, M. M. Durkin, M. M. Shaw, and J. W. Smith. 1991. Inoculated mouse model of Pneumocystis carinii infection. Diagn. Microbiol. Infect. Dis. 15:129-134.
3. Bartlett, M. S., S. Queener, M. Shaw, J. Richardson, and J. Smith. 1994. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob. Agents Chemother. 38:1859-1861.
4. Bray, M. V., S. W. Barthold, C. L. Sidman, J. B. Roths, and A. S. Smith. 1993. Exacerbation of Pneumocystis carinii pneumonia in immunodeficient (scid) mice by concurrent infection with a pneumovirus. Infect. Immun. 61:1586-1588.
5. Comley, J. C., and A. M. Sterling. 1994. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of anti-pneumocystis drugs. J. Eukaryot. Microbiol. 41:540-546.
6. Comley, J. C. W., and A. M. Sterling. 1995. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob. Agents Chemother. 39:806-811.
7. Comley, J. C. W., C. L. Yeates, and T. J. Frend. 1995. Antipneumocystis activity of 17C91, a prodrug of atovaquone. Antimicrob. Agents Chemother. 39:2217-2219.
8. Daniel, W. W. 1991. Biostatistics: a foundation for analysis in the health sciences, p. 274-365. John Wiley & Sons, Inc., New York, N.Y.
9. Fishman, J. A., S. F. Queener, R. S. Roth, and M. S. Bartlett. 1993. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model. Antimicrob. Agents Chemother. 37:1543-1546.
10. Frenkel, J. K., J. T. Good, and J. A. Schultz. 1966. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab. Invest. 15:1559-1577.
11. Graybill, J. R. 1986. Animal models for treatment of cryptococcus, p. 131-148. In O. Zak (ed.), Experimental models in antimicrobial chemotherapy. Academic Press, London, United Kingdom.
12. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
13. Hughes, W. T., J. Killmar, and H. Oz. 1994. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. J. Infect. Dis. 170:906-911.
14. Hughes, W. T., P. C. McNabb, and T. D. Makres. 1974. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother 5:289-293.
15. Kim, C. K., J. M. Foy, M. T. Cushion, D. Stanforth, M. J. Linke, H. L. Hendrix, and P. D. Walzer. 1987. Comparison of histologic and quantitative techniques in the evaluation of experimental Pneumocystis carinii. Antimicrob. Agents Chemother. 31:197-201.
16. Kitamura, D., J. Roes, R. Kuhn, and K. A. Rajewsky. 1996. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature 350:423-426.
17. Marcotte, H., D. Levesque, K. Delanay, et al. 1996. Pneumocystis carinii infection in transgenic B cell-deficient mice. J. Infect. Dis. 173:1034-1037.
18. McFadden, D., M. A. Powles, J. G. Smith, A. M. Flattery, K. Bartizal, and D. M. Schmatz. 1994. Use of anti-CD4 hybridoma cells to induce Pneumocystis carinii in mice. Infect. Immun. 62:4887-4892.
19. Powles, M. A., D. C. McFadden, L. A. Pittarelli, and D. M. Schmatz. 1992. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect. Immun. 60:1397-1400.
20. Roths, J. B., J. D. Marshall, R. D. Allen, G. A. Carlson, and C. L. Sidman. 1990. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Am. J. Pathol. 136:1173-1186.
21. Roths, J. B., and C. L. Sidman. 1992. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ cells into combined immunodeficiency mice. J. Clin. Invest. 90:673-678.
22. Roths, J. B., and C. L. Sidman. Lethal Pneumocystis carinii in B cell-deficient uMT mice. Submitted for publication.
23. Roths, J. B., A. L. Smith, and C. L. Sidman. 1993. Lethal exacerbation of Pneumocystis carinii pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice. J. Exp. Med. 177:1193-1198.
24. Shellito, J., V. V. Suzura, W. Blumenfeld, J. M. Beck, •. Stekger, and T. H. Ermak. 1990. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Invest. 85:1686-1693.
25. Sidman, C. L., and J. B. Roths. 1994. New animal models for Pneumocystis carinii research: immunodeficient mice, p. 223-235. In P. D. Walzer (ed.), Pneumocystis carinii pneumonia. Marcel Dekker, Inc., New York, N. Y.
26. Smith, T. J., S. F. Queener, M. S. Bartlett, M. M. Shaw, and J. W. Smith. 1994. Abstract presented at the American Society of Tropical Medicine and Hygiene. 43rd Annual Meeting.
27. 26a. Stringer, J. R., and P. D. Walzer. 1996. Molecular biology and epidemiology of Pneumocystis carinii infection. AIDS 10:561-571.
28. Walzer, P. D. 1991. Overview of animal models of Pneumocystis carinii pneumonia. J. Protozool. 38(Suppl):122-123.
29. Walzer, P. D., J. Foy, J. Runck, P. Steele, M. White, R. S. Klein, B. A. Otter, and R. J. Sundberg. 1994. Guanylhydrazones in treatment of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob. Agents Chemother. 38:2572-2576.
30. Walzer, P. D., J. Foy, P. Steele, and M. White. 1993. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone in the therapy of experimental pneumocystosis. Antimicrob. Agents Chemother. 37:1436-1443.
31. Walzer, P. D., J. Foy, P. E. Steele, C. K. Kim, M. White, R. Klein, B. Otter, and C. Allegra. 1992. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36:1935-1942.
32. Walzer, P. D., J. Foy, P. Steele, and M. White. 1992. Treatment of experimental pneumocystosis: review of seven years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother, 36:1943-1950.
33. Walzer, P. D., C. K. Kim, J. M. Foy, M. J. Linke, and M. T. Cushion. 1988. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 32:96-103.
34. Walzer, P. D., C. K. Kim, M. J. Linke, C. L. Pogue, M. J. Huerkamp, C. E. Chrisp, A. V. Lerro, S. K. Wixson, E. Hall, and L. D. Shultz. 1989. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect. Immun. 57:62-70.
35. Walzer, P. D., R. D. Powell, K. Yoneda, M. E. Rutledge, and J. E. Milder. 1980. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect. Immun. 27:929-937.
36. Walzer, P. D., R. D. Powell, and K. Yoneda. 1979. Pneumocystis carinii pneumonia in different strains of cortisonized mice. Infect. Immun. 24:919-947.
37. Walzer, P. D., J. Runck, S. Orr, J. Foy, P. Steele, and M. White. 1997. Clinically used antimicrobial drugs against experimental pneumocystosis. singly and in combination: analysis of drug interactions and efficacies. Antimicrob. Agents Chemother. 41:242-250.
38. Walzer, P. D., and M. E. Rutledge. 1982. Serum antibody responses to Pneumocystis carinii among different strains of normal and athymic (nude) mice. Infect. Immun. 35:620-626.
39. Walzer, P. D., M. E. Rutledge, and K. Yoneda. 1983. Experimental Pneumocystis carinii pneumonia in C3H/HeJ and C3HeB/FeJ mice. J. Reticuloendothel. Soc. 33:1-9.
40. Walzer, P. D., V. Schnelle, D. Armstrong, and P. P. Rosen. 1977. The nude mouse: a new experimental model for Pneumocystis carinii infection. Science 197:177-179.
41. Walzer, P. D., M. Labine, T. J. Redington, and M. T. Cushion. 1984. Lymphocyte changes during chronic administration and withdrawal of corticosteroids: relevance to Pneumocystis carinii pneumonia. J. Immunol. 133: 2502-2508.
42. Yasuoka, A., S. Oka, K. Komuro, H. Shimizu, K. Kitada, Y. Nakamura, S. Shibahara, T. Takeuchi, S. Kondo, K. Shimada, and S. Kimura. 1995. Successful treatment of Pneumocystis carinii pneumonia in mice with benanomicin A (ME1451). Antimicrob. Agents Chemother. 39:720-724.